VORVor Biopharma Inc.

Healthcare
$18.24-31% 1Y

The financials

Vor Biopharma Inc. by the numbers

Vor Biopharma Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$48M−$274Mn/a
Net income−$63M−$1.57Bn/a
Diluted EPS−$1.16−$251.24n/a

Biotechnology

Ranks #127 of 194 by RyuScore

Compare peers
REPL-4.7%
Replimune Group, Inc.
YDES+18%
YD Bio Ltd
SPTX-1.5%
Seaport Therapeutics, Inc.
GHRS-2.4%
GH Research PLC
AVBP+9.3%
ArriVent BioPharma, Inc.
BCAX-3.2%
Bicara Therapeutics Inc.